GSK and Hansoh Pharma announced that they have entered into an exclusive license agreement for HS-20089, a B7-H4 targeted antibody-drug conjugate, ADC, currently in phase I clinical trials in China. Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation of HS-20089. Hesham Abdullah, SVP, Global Head Oncology, R&D, GSK, said: “Given early clinical data, we believe that HS-20089 has best-in-class potential in ovarian and endometrial cancer with opportunities in other solid tumours. This agreement is in line with our approach to advancing novel treatment options for patients with gynaecologic cancers.” This agreement builds on GSK’s strategic R&D focus on tumour-cell targeting modalities as well as expertise in gynaecologic cancers including a significant medical and commercial presence. GSK plans to begin phase I trials outside of China in 2024. Terms of the agreement: Under the terms of this agreement, GSK will pay an $85 million upfront payment. In addition, Hansoh will be eligible to receive up to $1.485 billion in success-based milestones for HS-20089. Upon commercialisation of HS-20089, GSK will also pay tiered royalties on global net sales outside of China’s mainland, Hong Kong, Macau, and Taiwan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK announces CHMP of EMA adopted positive opinion of Jemperli
- GSK to present new data from B-Together phase IIb trial at AASLD meeting
- GSK settlement of California bellwether cases removes near-term risk, says BofA
- GSK confirms confidential settlement reached in Cantlay/Harper Zantac case
- GlaxoSmithKline (NYSE:GSK) Gains on £2.5B Deal for Shingles Vaccine in China